Perceptive Advisors Poised to Benefit from Biopharma IPO
The health care-focused hedge fund firm plans to add to its stake when Kodiak Sciences goes public next week.
Stephen TaubSeptember 26, 2018
Joseph Edelman, chief executive officer of Perceptive Advisors
(Chris Goodney/Bloomberg)
It may not be one of those hot-shot internet unicorns, but when Kodiak Sciences goes public — possibly next Wednesday — at least one hedge fund firm stands to benefit in a big way. Joseph Edelman’s Perceptive Advisors is an investor in the development-stage biopharmaceutical company,
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.